FDA Approved: PERJETA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for PERJETA (pertuzumab) from Genentech, Inc., resulting in updated labeling under the existing approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer

Drugs mentioned

• Perjeta (pertuzumab)

Snippet

SUPPL AP for PERJETA (PERTUZUMAB)